Exact Sciences Corp
EXAS46.950USD
+0.150+0.32%
Close 07/31, 16:00（ET）Quotes delayed by 15 min
8.85BMarket Cap
LossP/E TTM
More Details of Exact Sciences Corp Company
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Company Info
Ticker SymbolEXAS
Company nameExact Sciences Corp
IPO dateJan 30, 2001
Founded at1995
CEOMr. Kevin T. Conroy
Number of employees6900
Security typeOrdinary Share
Fiscal year-endJan 30
Address5505 Endeavor Lane
CityMADISON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code53719
Phone16082845700
Websitehttps://www.exactsciences.com/
Ticker SymbolEXAS
IPO dateJan 30, 2001
Founded at1995
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Kevin T. Conroy
Mr. Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.14M
-20.54%
Ms. Katherine S. (Kay) Zanotti
Ms. Katherine S. (Kay) Zanotti
Independent Director
Independent Director
72.76K
+3.10%
Mr. Daniel J. (Dan) Levangie
Mr. Daniel J. (Dan) Levangie
Independent Director
Independent Director
34.31K
+18.67%
Ms. Shacey Petrovic
Ms. Shacey Petrovic
Independent Director
Independent Director
28.90K
+22.97%
Mr. Brian Baranick
Mr. Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Executive Vice President, General Manager - Precision Oncology
23.26K
+0.94%
Ms. Leslie L. Trigg
Ms. Leslie L. Trigg
Independent Director
Independent Director
17.17K
+80.75%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
16.38K
+156.47%
Mr. Aaron Bloomer
Mr. Aaron Bloomer
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
13.84K
--
Mr. Michael J. (Mike) Barber, M.D.
Mr. Michael J. (Mike) Barber, M.D.
Independent Director
Independent Director
13.14K
+121.18%
Mr. James E. Doyle
Mr. James E. Doyle
Lead Independent Director
Lead Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Kevin T. Conroy
Mr. Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.14M
-20.54%
Ms. Katherine S. (Kay) Zanotti
Ms. Katherine S. (Kay) Zanotti
Independent Director
Independent Director
72.76K
+3.10%
Mr. Daniel J. (Dan) Levangie
Mr. Daniel J. (Dan) Levangie
Independent Director
Independent Director
34.31K
+18.67%
Ms. Shacey Petrovic
Ms. Shacey Petrovic
Independent Director
Independent Director
28.90K
+22.97%
Mr. Brian Baranick
Mr. Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Executive Vice President, General Manager - Precision Oncology
23.26K
+0.94%
Ms. Leslie L. Trigg
Ms. Leslie L. Trigg
Independent Director
Independent Director
17.17K
+80.75%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Commercial
332.50M
47.04%
Medicare Parts B & C
247.89M
35.07%
Other
74.81M
10.58%
International
51.59M
7.30%
By RegionUSD
Name
Revenue
Proportion
United States (Country)
655.20M
92.70%
Outside of united states
51.59M
7.30%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Commercial
332.50M
47.04%
Medicare Parts B & C
247.89M
35.07%
Other
74.81M
10.58%
International
51.59M
7.30%
Shareholding Stats
Updated: Wed, Jul 23
Updated: Wed, Jul 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
12.80%
Capital World Investors
9.45%
The Vanguard Group, Inc.
9.31%
Wellington Management Company, LLP
6.63%
BlackRock Institutional Trust Company, N.A.
4.07%
Other
57.74%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
12.80%
Capital World Investors
9.45%
The Vanguard Group, Inc.
9.31%
Wellington Management Company, LLP
6.63%
BlackRock Institutional Trust Company, N.A.
4.07%
Other
57.74%
Shareholder Types
Shareholders
Proportion
Investment Advisor
60.66%
Investment Advisor/Hedge Fund
28.14%
Hedge Fund
4.34%
Research Firm
2.48%
Bank and Trust
1.36%
Pension Fund
1.14%
Individual Investor
0.92%
Sovereign Wealth Fund
0.54%
Private Equity
0.36%
Other
0.05%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
1397
201.71M
106.93%
+2.11M
2025Q1
1424
199.78M
106.03%
-445.52K
2024Q4
1411
200.72M
108.09%
-225.66K
2024Q3
1375
190.82M
103.28%
-5.17M
2024Q2
1358
185.25M
100.40%
+6.59M
2024Q1
1347
168.41M
92.78%
-6.10M
2023Q4
1356
165.31M
91.41%
-11.01M
2023Q3
1337
167.70M
92.83%
-6.22M
2023Q2
1354
166.38M
92.24%
-10.65M
2023Q1
1343
167.01M
92.90%
-8.56M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
24.14M
12.8%
+5.29M
+28.03%
Mar 31, 2025
Capital World Investors
17.84M
9.45%
+297.66K
+1.70%
Mar 31, 2025
The Vanguard Group, Inc.
17.56M
9.31%
+616.59K
+3.64%
Mar 31, 2025
Wellington Management Company, LLP
12.50M
6.63%
+442.78K
+3.67%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.68M
4.07%
+12.62K
+0.16%
Mar 31, 2025
State Street Global Advisors (US)
6.61M
3.51%
+381.12K
+6.11%
Mar 31, 2025
T. Rowe Price Associates, Inc.
6.25M
3.32%
+631.23K
+11.22%
Mar 31, 2025
Fidelity Institutional Asset Management
3.59M
1.9%
+1.68M
+88.60%
Mar 31, 2025
Mackenzie Investments
3.28M
1.74%
+362.31K
+12.41%
Mar 31, 2025
Geode Capital Management, L.L.C.
3.27M
1.73%
+143.64K
+4.60%
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
First Trust NYSE Arca Biotechnology Index Fund
3.97%
First Trust Nasdaq Lux Digi Health Solutions ETF
3.96%
Invesco Biotechnology & Genome ETF
3.25%
SPDR S&P Biotech ETF
2.41%
First Trust Indxx Medical Devices ETF
2.39%
Capital Group US Small and Mid Cap ETF
2.22%
Franklin Genomic Advancements ETF
2.18%
Nuveen ESG Mid-Cap Growth ETF
2.09%
iShares Health Innovation Active ETF
2.07%
ROBO Global Healthcare Technology & Innovation ETF
1.97%
View more
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.97%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion3.96%
Invesco Biotechnology & Genome ETF
Proportion3.25%
SPDR S&P Biotech ETF
Proportion2.41%
First Trust Indxx Medical Devices ETF
Proportion2.39%
Capital Group US Small and Mid Cap ETF
Proportion2.22%
Franklin Genomic Advancements ETF
Proportion2.18%
Nuveen ESG Mid-Cap Growth ETF
Proportion2.09%
iShares Health Innovation Active ETF
Proportion2.07%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.97%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
